by Jose Varghese, Washington Alves, Benjamin J. Brill, Matt Wallace, David Calabrese, Alexander Regamey, and Pierre-Alain Girod
Volume 7, Issue 4 (Winter 2008)
Since the first approval for human use of a recombinant protein therapeutic, this sector of the pharmaceutical market has grown rapidly. The first approved protein therapeutics were small, non-glycosylated proteins such as insulin and human growth hormone; they were produced in bacterial systems. With the advent of mammalian cell-based production systems, it became possible to produce more complex, glycosylated proteins for use as recombinant therapeutics…
Citation:
Varghese J, Alves W, Brill BJ, Wallace M, Calabrese D, Regamey A, Girod P. Rapid Development of High-Performance Stable Mammalian Cell Lines for Improved Clinical Development. BioProcess J, 2008; 7(4): 30-36. http://dx.doi.org/10.12665/J74.Varghese